A New Target Emerges: How Platelet Channels Fuel Thrombosis in a Cancer-Linked Syndrome
A study in *Arthritis & Rheumatology* reveals a specific molecular mechanism driving thrombosis in antiphospholipid syndrome (APS), an autoimmune condition that significantly increases the risk of blood clots. Researchers found that platelets from APS patients exhibit abnormally high activity of pannexin-1 (PANX1) channels, leading to excessive release of ATP. This extracellular ATP then activates P2X receptors on the platelet surface, creating a self-reinforcing, calcium-dependent signaling loop that amplifies platelet activation, P-selectin exposure, and aggregation. Crucially, antibodies from APS patients were shown to directly trigger this pathway by enhancing phosphorylation of the PANX1 channel. The study demonstrates that pharmacological inhibition of PANX1 with carbenoxolone can normalize this prothrombotic platelet behavior, suggesting a potential therapeutic strategy.
Why it might matter to you: This research identifies PANX1 as a precise, druggable node within a pathogenic signaling cascade relevant to cancer-associated thrombosis. For oncologists, understanding this link between autoantibodies, platelet biology, and hypercoagulability is critical, as APS can occur secondary to malignancies. The findings suggest that targeting PANX1 could offer a novel approach to mitigate thrombosis without broadly impairing hemostasis, a valuable consideration for patients undergoing cancer treatments who are at high risk for clotting complications.
Source →Stay curious. Stay informed — with Science Briefing.
Always double check the original article for accuracy.